DEStiny® Sirolimus-Eluting Coronary Stent (DES) — Swiss Engineering for Interventional Cardiology The DEStiny® coronary stent, manufactured by IHT SA (Switzerland), is a premium cobalt-chromium drug-eluting stent (DES) designed for superior clinical outcomes in treating coronary artery disease. Key Benefits: Advanced Drug Delivery: Features a Sirolimus (Rapamycin) coating in a biodegradable PLLA polymer matrix, significantly reducing the risk of in-stent restenosis. Ultra-Thin Struts: The 80–90 µm thin-strut design provides excellent flexibility, exceptional trackability, and optimal vessel scaffolding. Rapid Exchange (RX) System: Pre-mounted on a high-performance delivery system, ensuring precise positioning and ease of use for the interventionist. Innovative Open-Cell Design: Promotes rapid endothelialization and ensures perfect conformity to the vessel wall anatomy.
IHT Central Asia LLP is a Kazakh-Spanish joint venture and the only manufacturer of coronary stents and balloon catheters in Central Asia, established in 2023. The company produces high-tech interventional cardiology devices based on European technology transfer. Production is localized in Astana and focused on treating ischemic heart disease and preventing myocardial infarction. Product range: Drug-eluting coronary stents (DEStiny) Balloon catheters for angioplasty (Evolve) Solutions for percutaneous coronary interventions Key advantages: Unique regional manufacturer Proven European technology and clinical validation Coverage of Kazakhstan demand (up to 36,000 stents/year) Up to 30% lower cost than imports Export to Central Asia and other markets IHT Central Asia delivers advanced cardiovascular solutions focused on technology, accessibility, and reliability for healthcare systems.
